Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
暂无分享,去创建一个
Z. Estrov | H. Kantarjian | G. Garcia-Manero | K. Patel | F. Ravandi | Koichi Takahashi | E. Jabbour | R. Kanagal-Shamanna | S. Kornblau | Wanlong Ma | M. Albitar | R. Assi | N. Short | R. Luthra | Ghayas C. Issa | J. Matthews | S. Loghavi | Feng Wang | G. Montalban-Bravo | M. Franquiz | G. Issa
[1] F. Ravandi,et al. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? , 2019, Haematologica.
[2] S. Miyano,et al. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. , 2019, Blood.
[3] Tristan J. Lubinski,et al. Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance. , 2019, JCO precision oncology.
[4] J. Cortes,et al. Acute myeloid leukaemia , 2018, The Lancet.
[5] Charles Swanton,et al. Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection , 2018, Nature Reviews Clinical Oncology.
[6] P. A. Futreal,et al. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Markus G. Manz,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.
[8] Jesse J. Salk,et al. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations , 2018, Nature Reviews Genetics.
[9] L. Miguet,et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. , 2018, The New England journal of medicine.
[10] M. Konopleva,et al. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia , 2017, Cancer.
[11] M. Konopleva,et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia , 2017, Cancer.
[12] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[13] Sung-Soo Yoon,et al. BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors , 2017, Haematologica.
[14] V. Carlton,et al. Next‐generation sequencing‐based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma , 2016, British journal of haematology.
[15] M. Baccarani. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[16] AlbitarFerras,et al. Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome , 2016 .
[17] G. Schuurhuis,et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia , 2016, Leukemia.
[18] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[19] Wanlong Ma,et al. Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome. , 2016, Genetic testing and molecular biomarkers.
[20] E. Shpall,et al. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] Christopher A. Miller,et al. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. , 2015, JAMA.
[22] L. Staudt,et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. , 2015, The Lancet. Oncology.
[23] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[24] R. Hills,et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. , 2007, Blood.
[25] A. Venditti,et al. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. , 2007, Haematologica.
[26] A. Giuliano,et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] E. Estey,et al. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing , 2001, Leukemia.